gretel
21 Dec 2016
Great new article about SDI [link] really good info, including: - the existing stellar list of blue chip shareholders increasing their holdings - a new institution on board - more acquisitions likely - Artemis "flying" and trading above expectations - ProReveal still with exciting upside in for free - talk of a dividend next year - a P/E of only 8 or 9, even before stripping out the net cash
gretel
20 Dec 2016
Finncap increase target price to 20p Finncap have increased their target price to 20p.They've conservatively adjusted their forecasts, leaving them at 1.7p EPS this year and going for 1.9p EPS next year.They also see SDI having a £1.1m cash pile at the end of this year, rising to £1.7m at Apr'18.This perhaps gives room for a further acquisition from part-cash, part-debt/fundraising.It's also worth noting that today's RNS says that "current trading of the Company is in line with expectations" for H1 to 31/10/16, which is encouraging.SDI still looks pretty cheap at the current price on that basis at 15p-16p.
gretel
20 Dec 2016
Exciting new acquisition today Astles looks a very good acquisition - and at an excellent price.£3.45m initial consideration and £4.8m on achievement of targets, compared to historic £0.87m PBT - that's extremely cheap. Especially if it achieves the £1.2m PBT necessary for the earn-out.Plus there are synergies and the likelihood of additional Sentek sales to Astles, which is already a Sentek customer The placing price is at too much of a discount, but I'd guess this was all done in a hurry pre-Christmas and the institution wanted their pound of flesh. Overall this looks a terrific bulking-up and heavily earnings-enhancing acquisition.
gretel
21 Nov 2016
New highs, buying above the offer price More new highs...yet still on a single-figure P/E and with lots of cash in the bank.Encouraging to see a buy at 18p right at the end of the day - a full 1p above the closing 17p offer.Hopefully bodes well for tomorrow.
gretel
17 Nov 2016
Moving up, and a new appointment Interesting to see the spread fall to a mere 0.5p now at 14.5p-15p. Very unusual for this stock.And here's a very impressive new appointment for a microcap company:[link] CEO for SynopticsCambridge, UK: Synoptics, a world leader in the development and manufacture of innovative digital imaging systems for life science and clinical applications, is pleased to announce the appointment of Dr Brian Stammers as its new CEO. Brian’s wealth of experience in the life science industry will help guide Synoptics’s strategic direction to deliver innovative and commercially successful products.As the CEO of Synoptics, which is part of the AIM quoted UK company Scientific Digital Imaging (SDI), Dr Stammers will oversee the commercial and technical direction of Synoptics’s three divisions, Syngene, Synbiosis and Synoptics Health.Brian is a life science expert having been active in the sector for over 35 years. He has spent the past five years working as an International Trade Adviser for UK Trade & Investment (UKTI) helping life science companies realise their international business ambitions. Prior to this, he held several MD/CEO roles with major life science companies, including B&T (part of the E. Merck empire); Difco Laboratories (now part of Becton Dickinson) and Lab-M. He has also been the CEO of two successful university spin-out companies, where he raised venture finance.Additionally, Brian has chaired and been president of UK Trade Association, The British Laboratoryware Association (BLWA) and was instrumental in merging the BLWA with GAMBICA, the Trade Association for Instrumentation, Control, Automation and Laboratory Technology. He is also a Freeman of the City of London.Brian’s vast commercial expertise is underpinned by five years’ working as a research scientist in a leading pharmaceutical company, as well as a degree in Zoology and a Ph.D. in Parasitology both from the University of London.Commenting on his appointment, Dr Stammers said: “I have worked closely with the Synbiosis division of Synoptics through UKTI for two years and I can see where my strategic guidance would make a significant difference to the commercial direction of the other divisions in the group. I’m looking forward to the opportunity of bringing that insight as the Synoptics group’s CEO.”Mike Creedon, SDI’s CEO, added: “We are delighted to appoint such a capable CEO for the Synoptics Group. We believe Brian will make a meaningful contribution to building a thriving commercial product portfolio, which scientist across the globe will actively choose for improving the throughput and quality of their research.”
gretel
15 Nov 2016
Moving up today with around £18k bought in two buys. Nice share price bounce recently.With forecasts still at 1.8p EPS this year and 1.9p EPS next year, plus a cash pile for more acquisitions, this still looks extremely cheap assuming trading remains on track as per the results outlook.
gretel
01 Nov 2016
News flow from SDI Nice mention for Sentek here as a "prominent player":[link] "Global Soil Moisture Sensors Market to Exhibit 15% CAGR 2016–2020 as Need for Improving Agricultural Productivity Rises Albany, NY -- (SBWIRE) -- 10/18/2016 -- The 56-page research report, titled "Global Soil Moisture Sensors Market 2016-2020," offers a thorough overview of the market. The product segmentation, growth drivers, challenges, key geographical segments, and the competitive landscape of the global soil moisture sensors market have been discussed at length in the research study. As per the research report, the global market for soil moisture sensors is estimated to register a strong 15% CAGR between 2016 and 2020. The growing necessity for conservation of water in irrigation systems and growth of environment-focused NGOs and regulatory bodies are the primary factors estimated to drive the demand for soil moisture sensors. In addition, the need to improve agricultural productivity by measurement of soil moisture content is expected to augment the growth of the market in the coming years. However, the low rate of adoption in emerging economies is projected to restrict the growth of the market. Read more: hxxp://www.digitaljournal.com/pr/3110147#ixzz4OMup3t5z etc" And also a new software upgrade from Atik:[link] "Atik Infinity Software Version 1.4 Released October 17th, 2016 We’re very pleased to announce the release of Infinity Version 1.4. This latest release features a number of updates, such as new saturation and brightness controls and the ability to add cross hairs to an image, but perhaps our favourite of the latest additions is the introduction of fine histogram controls. These allow you to make much more delicate adjustments to the levels on the histogram, resulting in finer control over the display of your images. etc"
gretel
04 Oct 2016
Rise caused by sizeable buy Looks like a late reported 100k buy at 15p was the cause of yesterday's rise....
gretel
23 Aug 2016
Good coverage of new DNA product [link] imaging firm Syngene has introduced the NuGenius, which it says is the first gel imaging system in the world to be run by a Raspberry Pi. It quickly generates high quality images of DNA gels and can be used in various applications such as detecting disease-causing genes."
gretel
07 Aug 2016
SDI reveal new DNA imaging system What an innovative company this is - another new product being brought to market last month in an area where it is already the leader:[link] upside potential from these various new products, as well as having a solid Balance Sheet with a £1m+ and rising cash pile and cheap fundamentals at a 14p share price against historic 1.7p EPS.
gretel
04 Aug 2016
New ProReveal video from the USA This video will surely bring in terrific interest for ProReveal from the USA. What a great speaker too, most entertaining and informative (though you can skip the first few minutes):[link] summary of the video from a poster elsewhere sums it up nicely:"This is from just last month where there is a clear mention on the new DOH guidance along with some compelling reasons for adopting the ProReveal tech.The man speaking is Dr David Perrett who was a key player in the development team which SDI's arm worked with on the development and who remains of some industry importance.If you can get past the early history lesson in the video, I feel its a great intro to the background, tech and more importantly the reasons for any Hospital to take it up, which may at last be sooner rather than later on the back of that latest DOH guidance.For the record and as we know, the system was developed jointly and the patent is owned by SDI and the Queen Mary Hospital,although SDI has the rest, which includes the consumables as in the spray which from the video it says lasts up to six months.That surely means if ProReveal gets any momentum behind it in the future there should be a nice nice recurring element of revenue."
gretel
28 Jul 2016
SDI article by Private Punter Great new article by the Private Punter:[link] stock is extremely undervalued imo. Nice to see 192, 685 shares bought in two lots yesterday at 13.45p.
gretel
22 Jul 2016
Finncap see 50% upside Finncap have calculated 1.7p historic EPS, so even better than I thought - their's is probably on shares in issue rather than fully diluted as mine was.They also note £1.4m net cash, although to my eyes there's £1.7m cash less £0.7m debt, i.e £1m net cash. I suspect SDI will pick up some tip/press interest which will help things along nicely.Finncap's 19p price target seems pretty conservative to me given their 1.8p forecast EPS - and a £2.3m cash pile at April'17 against the current £8m m/cap. Plus Proreveal's blue sky potential et al.
gretel
22 Jul 2016
Terrific results and outlook today Excellent results - 1.59p adjusted EPS is better than expectations, and everything else is spot on:[link] a £7.4m m/cap SDI is very, very undervalued imho:- 1.59p historic adjusted EPS (fully diluted) - almost doubled on last year- £1m net cash- blue sky potential of Proreveal in for nothing- more acquisitions likely(PS : they should have published the adjusted EPS figure themselves)And very bullish comments:"The Board is confident that SDI is now in an excellent position for continued good growth through increased revenue and the potential for further acquisitions in 2016/17""The Board expects SDI to make good progress over the coming financial year as we will continue to pursue our strategy of organic and acquisitive growth. As well as the positive contribution of Sentek, Opus Instruments and Atik, the new Synoptics products released in 2016, together with a focused sales strategy, are expected to drive continued growth.With growing interest in our products from North America, particularly in the rapid microbiology and antibiotic resistance testing sectors, the Board views the next financial year with confidence."
gretel
21 Jul 2016
Rising on unusually large trades Unusually large transactions yesterday - 200,000 were bought at 11p, plus 80k and 154k at 10.5p which I suspect were also buys from earlier in the day.
